Kurse werden geladen...
Prognose
Für dieses Unternehmen liegen uns keine Analysten-Daten vor.
Scoring-Modelle
Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.
Beliebteste Broker
News
- 30.08. - 12:30 Uhr
Rapha Capital Leads New $3 Million Convertible Note Financing in Imagin Medical, Inc.
MIAMI and VANCOUVER, BC and BOSTON, Aug. 30, 2021 /PRNewswire/ -- Rapha Capital Management, LLC ("Rapha Capital") today announces it has closed a new convertible note offering totaling US $3 million in three tranches by Rapha Capital BioVentures Fund I, LP ("RCBVFI") to support the clinical development of Imagin Medical Inc.'s (CSE: IME) (OTCQB: IMEXF) (Frankfurt & Stuttgart Symbol: DPD3) ("Imagin" or the "Company") lead product, the i/Blue™ Imaging System. Concurrent with this financing, Kevin Slawin, M.D. » Mehr auf prnewswire.com
- 26.08. - 20:56 Uhr
Imagin Medical Secures New $3 Million Convertible Note Financing
VANCOUVER, British Columbia, BOSTON and MIAMI, Aug. 26, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) (Frankfurt & Stuttgart Symbol: DPD2) (“Imagin” or the “Company”) today announces it has closed a new convertible note offering totaling US$3 million in three tranches by Rapha Capital BioVentures Fund I, LP (RCBVFI) to support the clinical development of Imagin's lead product, the i/Blue™ Imaging System. Concurrent with this financing, Kevin Slawin, M.D., a leading urooncologist and manager of the RCBVFI, will join Imagin's board of directors. In addition, with this financing, Imagin is launching its new enhanced website ( https://imaginmedical.com ), which display's the Company's new logo, to reflect the change in energy and direction of the Company. » Mehr auf globenewswire.com
- 17.08. - 12:30 Uhr
Imagin Medical on Schedule for American Urology Association Demonstration
VANCOUVER, British Columbia, and BOSTON, Aug. 17, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) (Frankfurt & Stuttgart Symbol: DPD2) (“Imagin” or the “Company”) today reports that the final design of the i/Blue Imaging System™ is on target to be demonstrated at the American Urology Association (AUA) Annual Meeting in September. » Mehr auf globenewswire.com
Historische Dividenden
Alle Dividenden KennzahlenUnternehmenszahlen
(EUR) | Juni 2023 | |
---|---|---|
Umsatz | 0,00 | - |
Bruttoeinkommen | 32,04k | - |
Nettoeinkommen | 1,52 Mio | - |
EBITDA | 214,37k | - |
Fundamentaldaten
Metrik | Wert |
---|---|
Marktkapitalisierung | 536,79k € |
Anzahl Aktien | 98,92 Mio |
52 Wochen-Hoch/Tief | 0,0809 € - 0,00092 € |
Dividenden | Nein |
Beta | 1,1 |
KGV (PE Ratio) | 0,07 |
KGWV (PEG Ratio) | 0,00 |
KBV (PB Ratio) | 0,01 |
KUV (PS Ratio) | 0,00 |
Unternehmensprofil
Imagin Medical Inc. ist ein Unternehmen für chirurgische Bildgebung mit Schwerpunkt auf Blasenkrebs. Das Unternehmen entwickelt das i/Blue Imaging System, um den Bedarf von Urologen an BLC zu decken. Imagin Medical Inc. wurde 1986 gegründet und hat seinen Hauptsitz in Vancouver, Kanada.
Name | Imagin Medical |
CEO | Edward James Hutchens |
Sitz | Vancouver,
bc Kanada |
Website | |
Börsengang | 23.01.2013 |
Mitarbeiter | 0 |
Ticker Symbole
Börse | Symbol |
---|---|
Pnk | IMEXF |
Frankfurt | DPD3.F |
München | DPD3.MU |
Assets entdecken
Shareholder von Imagin Medical investieren auch in folgende Assets